{"url":"https://newsforagent.com/news/2026-10-16/emergent-biosolutions-cfo-lindahl-retirement-vargo","markdown_url":"https://newsforagent.com/news/2026-10-16/emergent-biosolutions-cfo-lindahl-retirement-vargo.md","title":"Emergent BioSolutions CFO Lindahl to Retire, Vargo Interim","headline":"Emergent BioSolutions CFO Richard S. Lindahl to Retire December 31; Frank Vargo Named Interim CFO","description":"Emergent BioSolutions CFO Richard S. Lindahl retires December 31, 2026, and Frank Vargo becomes interim CFO on January 1, 2027, the company said.","section":"Leadership","published_at":"2026-10-16T12:13:37+00:00","modified_at":"2026-10-16T12:13:37+00:00","author":"News Desk","key_takeaways":["Richard S. Lindahl will retire as Emergent BioSolutions executive vice president and chief financial officer effective December 31, 2026.","Frank Vargo, vice president and treasurer, becomes interim chief financial officer effective January 1, 2027.","Lindahl will serve as a senior executive advisor from January 1 through March 31, 2027, to support the transition."],"companies":[{"name":"Emergent BioSolutions","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000hfv/emergent-biosolutions","website":"http://emergentbiosolutions.com"}],"source":{"publisher":"Business Wire","title":"Emergent BioSolutions names interim CFO for Jan. 1","url":"https://www.businesswire.com/news/home/20261016438347/en/"},"other_sources":[],"tags":["Leadership","Emergent BioSolutions"],"body_markdown":"[Emergent BioSolutions](https://akta.pro/company-profiles/0000hfv/emergent-biosolutions) executive vice president and chief financial officer Richard S. Lindahl will retire effective December 31, 2026, and Frank Vargo, vice president and treasurer, will become interim chief financial officer effective January 1, 2027, the company said in a [Business Wire](https://www.businesswire.com/news/home/20261016438347/en/) announcement. Lindahl will serve as a senior executive advisor from January 1 through March 31, 2027.\n\n## Lindahl's Retirement and Vargo's Interim Appointment\n\nEmergent BioSolutions said Lindahl's retirement takes effect December 31, 2026, and that Vargo, currently vice president and treasurer, will assume the interim chief financial officer role the following day. Lindahl will stay on as a senior executive advisor from January 1 through March 31, 2027, to support the transition.\n\nJoe Papa, president and chief executive officer of Emergent, said, \"On behalf of the Board of Directors and our colleagues, I want to thank Rich for his exceptional leadership, partnership and commitment to Emergent, and importantly, his dedication to our mission to protect and save lives.\" Papa added that Vargo, who joined Emergent in 2019, \"has been integral in driving our strategic priorities forward.\"\n\nBefore joining Emergent in 2018, Lindahl served as chief financial officer of CEB, senior vice president and treasurer of Sprint Nextel Corporation, and vice president of finance at Pocket Communications, Inc., and held positions at MCI Communications Corp. and Deloitte & Touche LLP. He serves on the board of directors of Compass Therapeutics, Inc.\n\nLindahl said, \"During my nearly nine years at Emergent, I am proud of the contributions our team made to the Company's growth, the resilience we demonstrated through some extraordinarily challenging periods, and the progress we made in strengthening the business for the future.\" The company said the leadership transition reflects its continued execution of a multi-year transformation plan.\n\n## Emergent BioSolutions' Recent Financing and Revenue\n\nEmergent BioSolutions closed a $150 million term loan with OrbiMed in April 2026 and amended its Wells Fargo asset-based revolver to up to $50 million, using proceeds to repay the Oak Hill Advisors term loan and extending maturities to April 2031 while reducing annual interest expense by 200 basis points, according to akta.pro [company records](https://akta.pro/company-data). The company reported fiscal 2025 revenue of $742.9 million, a 29% decline from $1.04 billion in 2024, and net income of $52.6 million versus a net loss of $190.6 million the prior year. First-quarter 2026 revenue was $156 million, down 30% from $222.2 million in the first quarter of 2025.\n\n## Emergent BioSolutions' Third-Quarter Earnings Call\n\nEmergent BioSolutions will host a conference call on November 2, 2026, to discuss its third-quarter 2026 financial results, Stock Titan reported. The call is scheduled for 5:00 p.m. eastern time, with dial-in numbers and a replay available on the company's website.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}